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Abstract
Purpose Complementary and alternative medicine (CAM) use is common amongst cancer patients. However, there is grow-
ing concern about its safety and efficacy. Online crowdfunding campaigns represent a unique avenue to understand the cancer 
patient’s perspective for using CAM or declining conventional cancer therapy (CCT).
Methods Five hundred GoFundMe campaigns from 2012 to 2019 detailing financial need for cancer treatment were randomly 
selected and reviewed for endorsement of CAM use, reasons for using CAM, and reasons for declining CCT. Descriptive 
statistics were used to compare patient and campaign characteristics between 250 CAM users and 250 non-CAM users.
Results Compared to non-CAM users, CAM users were more likely to be female (70% vs. 54%, p < 0.01), to report more 
stage IV cancer (54% vs. 12%, p < 0.01), and to have a history of delayed, missed, or misdiagnosis (10% vs. 4%, p < 0.01). 
Reasons for using CAM include endorsing curative/therapeutic effects 212 (85%), pain/stress reduction 137 (55%), and dis-
satisfaction with current or past medical treatment options 105 (42%). 87 (35%) CAM users that declined CCT reported that 
they wanted to try to fight off cancer using CAM first 57 (61%), that CCT was too “toxic” to the body 39 (42%), and cancer 
was already too advanced, so that CCT would be futile or too aggressive 25 (27%).
Conclusion Cancer patients on GoFundMe using CAM highly value quality of life, comfort, and autonomy. Physicians should 
educate themselves on CAM to set realistic expectations and provide comprehensive counseling of the risks and benefits of 
CAM usage to patients who choose to use CAM to either augment or completely replace CCT.
Keywords Complementary and alternative medicine · Social media · Crowdfunding · Cancer treatment · Patient 
perspective
Introduction
The national cost for cancer care is substantial, with expen-
ditures totaling an estimated $125 billion in 2010 (Mari-
otto et  al. 2010). Many cancer patients have turned to 
crowdfunding, the practice of soliciting monetary contri-
butions through social media, to cover costs (Cohen et al. 
2019). In addition to conventional cancer therapy (CCT) 
such as surgery, chemotherapy, and radiation, many cancer 
patients seek to crowdfund for complementary and alter-
native medicine (CAM) treatments as part of their medi-
cal care (Snyder and Caulfield 2019). A greater percentage 
of cancer patients use CAM than the general population 
(Anderson and Taylor 2012), with an estimated 48–84% of 
cancer patients reporting using CAM as part of their therapy 
(Johnson et al. 2018a; Richardson et al. 2000).
While there are many published studies extolling the ben-
efits of CAM use as an adjunct to CCT (Richardson et al. 
2000; Mansky and Wallerstedt 2006), there is still grow-
ing concern regarding the safety of CAM use (Snyder and 
Caulfield 2019), particularly when used as the sole cancer 
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treatment. Furthermore, prior studies have found an associa-
tion with CAM use and increased mortality mediated from 
refusal of CCT (Johnson et al. 2018a, b). Medical crowd-
funding for CAM may thus represent an avenue that enables 
cancer patients to raise funds for unproven and potentially 
dangerous treatment options (Vox et al. 2018).
Considering the potential risks involved with CAM use, 
it is important to better characterize users and their motiva-
tions for using CAM and declining CCT. Prior studies note 
motivations such as pain relief, psychological well-being, 
and controlling the side-effects of disease or treatment 
(Mansky and Wallerstedt 2006; Clarke et al. 2015; Barnes 
et al. 2002). However, these studies have relied on surveys 
that may not fully capture the patient perspective. With the 
advent of social media and technology, individuals are now 
free to detail their own narratives to easily disseminate infor-
mation to large audiences. These online cancer campaigns 
thus represent a unique avenue through which we can better 
understand the unfiltered patient perspective. Better under-
standing of CAM usage and refusal of CCT is crucial for 
providers to effectively counsel oncologic patients on their 
treatment options.
To better characterize CAM users, we examined crowd-
funding campaigns for cancer treatment from GoFundMe, 
the largest medical crowdfunding platform. Our objective 
was to compare CAM users and non-CAM users to under-
stand patients’ reasons behind CAM use and clarify their 
attitudes and beliefs towards CCT. We hypothesized that 
CAM users require substantial monetary support for their 
therapy and that many seek to use CAM to improve their 
comfort and quality of life.
Methods
Data source and selection of study cohort
Our methodology has been described previously (Cohen 
et al. 2019), but in brief: we identified the top 20 most preva-
lent cancers in the U.S. (National Cancer Institute at https 
://www.cance r.gov/). Each cancer and U.S. State were then 
queried on GoFundme.com for 1000 individual searches 
(50 states × 20 top cancers = 1000 batches of searches). We 
used web scraping and custom Python code to abstract and 
assemble website data for analysis to gather 37,344 total 
cancer campaigns. To select our study cohort, we then did 
a literature search and compiled a list of the top most uti-
lized CAM methods to inform our search terms (Clarke et al. 
2015). We wrote a Python code to extract out campaigns 
that mentioned any of the following search terms: “holis-
tic” (n = 458), “yoga” (n = 196), “chiropract” (n = 159), 
“acupuncture” (n = 130), “herbal” (n = 126), “meditation” 
(n = 123), “hyperbaric” (n = 84), “essential oils” (n = 67), 
“homeopath” (n = 66), “osteopath” (n = 20), “Ayurveda” 
(n = 10), “energy healing” (n = 8), “tai chi” (n = 7), “fish oil” 
(n = 6), “botanical” (n = 6), “qigong” (n = 5), and “chakra” 
(n = 3). A total of 1474 campaigns were identified, and 250 
campaigns were randomly selected to serve as our study 
cohort. Campaigns were excluded if the subject was non-
human (i.e., pets with cancer), intended for non-cancer ill-
nesses, did not explicitly mention past or current CAM use, 
or explicit interest in using CAM treatments in the future.
To better characterize our study cohort, 250 campaigns 
analyzed in our prior work that did not endorse CAM usage 
were also randomly selected to serve as our comparison 
cohort, using the randomizer tool in Stata 15 (College Sta-
tion, TX).
Variables
From each campaign narrative, patient demographics and 
clinical characteristics were identified, including: age; pri-
mary cancer type; cancer stage (I, II–III, IV, V, or higher); 
cancer status (metastasis, remission/cure, hospice/end of life, 
active treatment, recurrence, death); history of misdiagnosis, 
missed diagnosis, or delayed diagnosis; and insurance sta-
tus (covered, undercovered, and no insurance). We defined 
“covered” by any mention of having insurance coverage for 
medical care, excluding CAM treatments; “undercovered” 
by any mention of having insurance but struggling with any 
medical costs not covered by insurance; and “no insurance” 
by any mention of not having insurance.
We evaluated CAM usage of these subjects by identifying 
types of CAM used. For ease of descriptive analysis, CAM 
treatments themselves were grouped if similar. An explana-
tion of treatment groups can be found in Appendix 1. Main 
reasons for using CAM were also identified and separated 
into categories. We also examined intent to travel out of 
state for CAM treatment, the timing of CAM in relation to 
CCT, any past CCT interventions, future CCT interventions, 
perceptions of CCT as “toxic”, and ideas on the efficacy of 
CCT in comparison to CAM. Campaign characteristics were 
also collected and included goal funds, actual funds raised, 
and number of social media shares.
Statistical analysis
Descriptive statistics were used to describe both the study 
cohort and comparison cohort. Patient, clinical, and cam-
paign characteristics were stratified by CAM usage. Chi-
square and Fisher’s exact tests were used to compare cat-
egorical variables, and Wilcox’s rank sum test was used to 
compare continuous variables. p values < 0.05 were consid-
ered statistically significant. We used the R statistical suite 
for analysis (https ://www.r-proje ct.org/).
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Results
Five hundred total GoFundMe cancer campaigns were ana-
lyzed, with 250 campaigns that endorsed CAM use and 250 
campaigns that did not endorse CAM use. There were more 
female subjects among the CAM users than non-CAM users 
(70% vs. 54% respectively, p < 0.01) (Table 1). Breast can-
cer was the most common cancer type among both groups, 
although more prominent among CAM users than non-CAM 
users (31% vs. 21% respectively, p < 0.01). CAM users 
compared to non-CAM users also tended to have a higher 
cancer stage (stage IV or higher 54% vs. 12%, p < 0.01), a 
history of misdiagnosis, or delayed diagnosis (10% vs 4%, 
p < 0.01), and more likely to have insurance coverage (30% 
vs. 12%, p < 0.01). While there was no significant differ-
ence in past CCT between CAM and non-CAM users, there 
was a statistically significant difference in future surgery 
treatment between CAM and non-CAM users (2% vs. 7%, 
p = 0.04). CAM users also tended to have higher fundraising 
goals compared to non-CAM users (median $15,000, IQR: 
$10,000–35,000 vs. $10,000, IQR: $5000–20,000, respec-
tively, p < 0.001). CAM users also tended to raise more funds 
than non-CAM users (median $2870 IQR: $1160–7950 
vs. $2145 IQR: $912–5847 respectively, p = 0.02). CAM 
users also had a greater number of online shares (median 
$247, IQR: $97–494 vs. $179, IQR: $70–436 respectively, 
p = 0.04).
Figure 1 shows a visualization of the most frequently 
cited CAM treatments and their intersections (Conway et al. 
2017). The top 14 most used treatments were: special diets 
107( 43%), herbal 81 (33%), acupuncture 57 (23%), essen-
tial oils 46 (18%), oral vitamins and minerals 41 (16%), IV 
vitamins 23 (9%), hyperbaric oxygen/ozone treatments 21 
(8%), massage 17 (7%), teas 16 (6%), cannabidiol oil 16 
(6%), yoga 13 (5%), energy healing/Reiki 13 (5%), colon 
hydrotherapy 12 (5%), and spices 9 (4%). 81% of the cohort 
reported either already using or intending to use two or more 
CAM methods, while 16% reported using five or more CAM 
methods. Subjects either utilized CAM treatments under 
self-direction, under the supervision of outpatient naturo-
pathic/holistic medicine providers, or under inpatient treat-
ment programs at a holistic medicine center. 87 (35%) of 
these campaigns expressed interest or intent on traveling out 
of state for CAM treatment to a specific center.
Curative or therapeutic effects were cited as the top rea-
son subjects used CAM with 212 (85%) campaigns, followed 
by 137 (55%) campaigns endorsing pain and stress reduc-
tion (Table 2). 105 (42%) reported using CAM due to dissat-
isfaction with current or past medical treatment options: 45 
(18%) mentioned having no/limited viable medical options 
left due to the advanced nature of their cancer, 10 (4%) did 
not want to go through the negative side-effects of chemo 
or radiation, and 7 (3%) had already experienced the nega-
tive side-effects of CCT and were unwilling to tolerate any 
more. 63 (25%) reported using CAM for spiritual/emotional 
well-being and 28 (11%) reported religious beliefs as a main 
reason for utilizing CAM. 11 (4%) reported that financial 
barriers in accessing CCT were a reason for using CAM 
instead for cancer treatment. Only four (2%) said that CAM 
usage was a part of traditional cultural practices. Three (1%) 
mentioned a fear that CCT alone would not be enough/would 
not work.
In examining CAM usage in relation to CCT, 78 (31%) 
stated that they used only CAM as their only cancer treat-
ment, while 165 (66%) campaigns endorsed using both 
CAM and CCT. Of these 165 campaigns, 5 (2%) campaigns 
stated that they used CAM before starting CCT, 67 (27%) 
stated that they started utilizing CAM after completion of 
CCT, and 93 (37%) stated that they use both CAM and CCT 
concurrently.
We also found that 85 (34%) campaigns endorsed a belief 
that CAM is more effective than CCT. At the time of the 
campaign’s publication, 156 (62%) campaigns stated that 
the subject had tried CCT, while 87 (35%) stated that they 
had not. Out of these 87 campaigns, top reasons for declin-
ing CCT include: 57 (66%) wanted to try to fight off can-
cer using CAM first, 39 (45%) believed that CCT was too 
“toxic” or “poisonous” to the body. 25 (29%) campaigns 
stated that their cancer was already too advanced, and CCT 
would be futile or too aggressive. 17 (18%) campaigns said 
that they would undergo CCT eventually, but had not tried 
CCT by the time of the campaign’s publication. 9 (10%) 
mentioned financial obstacles that prevented them from 
undergoing CCT. 7 (8%) stated that negative personal expe-
riences, either having had CCT in the past or seeing another 
loved one using CCT, played the largest motivation to refuse 
CCT. Five (6%) stated that they did not trust the medical 
system or their providers to provide them with quality care.
Discussion
In this study of GoFundMe campaigns for cancer treat-
ment, CAM users were more likely to be female, have 
more advanced cancer stage, and have a history of delayed, 
missed, or misdiagnosis. CAM users requested $5000 more 
in donations than non-CAM users. Nearly a third of the sub-
jects endorsed past or future travel to a specialized CAM 
center for inpatient treatment, often internationally. Reasons 
for using CAM fell into four main categories: CCT as “toxic 
to the body and inferior to “natural” CAM methods; CAM as 
an adjunct to CCT; CAM as a last-resort option for aggres-
sive cancer/terminal stage without medical options; and 
CAM as a way to prioritize quality of life in their remaining 
years over curative efficacy. 34.8% of CAM users declined 
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Table 1  Comparison of CAM users and non-CAM users
*Other cancers include: bladder, cervical, kidney, non-Hodgkin lymphoma, prostate, skin (non-melanoma), melanoma, rectal, thyroid, uterine, 
Hodgkin lymphoma, soft tissue/muscle, and rare/non-specified cancers
Characteristic, n (%) CAM users, n = 250 n (%) Non-CAM users, n = 250 n (%) p value
Gender
 Female 176 (70) 135 (54) < 0.001
 Male 73 (30) 115 (46)
Cancer type 0.007
 Breast 77 (31) 53 (21)
 Colon 25 (10) 13 (5)
 Lung 19 (8) 30 (12)
 Leukemia 10 (4) 32 (13)
 Brain 9 (4) 9 (4)
 Liver 8 (3) 10 (4)
 Pancreatic 8 (3) 8 (3)
 Stomach 7 (3) 8 (3)
 Ovarian 7 (3) 6 (2)
 Other* 80 (32) 81 (32)
Cancer stage
 I 2 (1) 6 (2) < 0.001
 II or III 34 (14) 75 (30)
 IV or higher 135 (54) 30 (12)
History of misdiagnosis or delayed diagnosis? < 0.001
 Yes 26 (10) 9 (4)
 No 47 (19) 83 (33)
Insurance status < 0.001
 Covered 75 (30) 30 (12)
 Undercovered 45 (18) 50 (20)
 No insurance 18 (7) 22 (9)
Past treatment
 Chemotherapy only 38 (15) 57 (23) 0.070
 Surgery only 30 (12) 31 (12) 0.100
 Radiation + chemotherapy 20 (8) 12 (5) 0.100
 Radiation + surgery 9 (4) 7(3) 0.600
 Chemotherapy + surgery 20 (8) 26 (10) 0.600
 Radiation + chemotherapy + surgery 18 (7) 16 (6) 0.600
Future treatment
 Radiation only 7 (3) 6 (2) 0.400
 Chemotherapy only 19 (8) 32 (13) 0.400
 Surgery only 5 (2) 18 (7) 0.040
 Experimental only 8 (3) 4 (2) 0.100
 Radiation + chemotherapy 7 (3) 10 (4) 0.800
Goal funds
 Median, IQR 15,000 (10,000–35,000) 10,000 (5000–20,000) < 0.001
Funds raised
 Median, IQR 2870 (1160–7950) 2145 (912–5848) 0.020
Number of shares
 Median, IQR 247 (97–494) 179 (70–436) 0.040
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CCT usage and endorsed CAM as their sole method of can-
cer treatment. The three main reasons that subjects declined 
CCT overlap with reasons for CAM usage: the idea that CCT 
is more harmful to the body than beneficial; their cancer is 
already too aggressive and not wanting to subject themselves 
to any harsh or futile treatment; and prioritizing quality of 
life in their remaining years.
The most compelling finding in our study is that auton-
omy, comfort, and quality of life are extremely important 
to patients when considering which cancer treatment to 
undertake. Considering that the risk of morbidity associ-
ated with CAM use is mediated by patients’ refusal of CCT 
(Anderson and Taylor 2012), it is crucial to understand why 
certain cancer patients are refusing CCT in lieu of CAM 
treatment. We found that while some subjects chose CAM 
and declined CCT due to a subjective judgment of “natu-
ral” treatments being superior, a larger proportion of the 
patient narratives demonstrate a clear understanding of the 
risks and benefits of declining CCT. This is consistent with 
the previous studies examining patient motivations behind 
CAM usage, particularly in the setting of oncologic disease 
in alleviating both the symptoms of cancer and side-effects 
of CCT (Mansky and Wallerstedt 2006). In one study exam-
ining patients with locally-advanced breast cancer, CAM 
use in patients was associated with decreased anxiety and 
depression, a greater sense of control over their lives, and 
allowed patients to feel more hopeful regarding their chances 
Fig. 1  Types of CAM treatments used. This figure shows a graphic representation of the different CAM treatments endorsed by subjects in the 
study, by frequency and interactions (Helyer et al. 2006)
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of survival (Helyer et al. 2006). These are important aspects 
of CAM use that are likely drivers behind CAM usage.
Patients’ motivations for using CAM and declining CCT 
can inform future recommendations for providers. Cur-
rently, as many as 70% of patients may not disclose CAM 
usage to physicians, possibly out of fear of being misun-
derstood (Eisenberg et al. 1998; Boon et al. 2000). Under-
standing patients’ preferences to use CAM may improve the 
patient–doctor relationship and create a more therapeutic 
alliance. This can improve patient satisfaction as physicians 
take into consideration a patient’s preference for CAM 
(Mazurenko et al. 2017). Considering the growth of CAM 
usage and awareness over the past decade, with methods 
such as acupuncture or chiropractic medicine now covered 
by many insurance plans, providers should better understand 
these heavily utilized practices and utilize decision-making 
frameworks that can address each patient’s unique needs 
and beliefs (Weeks et al. 2014). Physicians should approach 
treatment counseling by focusing on the patient’s preference 
for autonomy, comfort, and quality of life (Verhoef et al. 
2005).
It is also paramount to educate patients on realistic 
expectations with CAM use. The ethics of marketing CAM 
therapy, often with promises of miracle cure-all effects, is a 
serious issue that deserves particular attention, especially as 
CAM use in the US continues to grow (Clarke et al. 2015; 
Barnes et al. 2007). Roughly $34 billion is spent annually 
on CAM (Herman et al. 2005) with two-thirds spent on self-
directed therapy ($22 billion) and one-third on practitioner 
visits ($11.9 billion) (Nahin et al. 2007). This may provide 
Table 2  Summary of key patient narratives
Reason(s) for using CAM
 Curative or therapeutic effects 212 (85)
 Pain or symptom relief, stress reduction 137 (55)
 Dissatisfaction with current or past medical treatment options 105 (42)
 Spiritual/emotional well-being 63 (25)
 Very limited/no viable medical options left 45 (18)
 Religious beliefs 28 (11)
 Does not want to go through the negative side-effects of chemo/radiation, but still wants some treatment 10 (4)
 Financial reasons 11 (4)
 Already experienced negative side-effects of chemotherapy/radiation, cannot tolerate it anymore 7 (2)
 Cultural beliefs 4 (2)
 Fear that conventional cancer therapy alone will not be enough/won’t work 3 (1)
 Other/unknown 13 (5)












Reasons for declining CCT 
 Want to try to fight off cancer using CAM first 57 (66)
 Too “toxic” or “poisonous” to the body 39 (45)
 Cancer is too advanced already; treatment either futile or too aggressive 25 (29)
 Will plan on undergoing conventional cancer treatment eventually 17 (20)
 Financial barriers/obstacles 9 (10)
 Negative personal experiences previously, either with self or another loved one, in regards to using chemo/radiation 7(8)
 Mistrust in the medical system 5 (6)
 Just want to enjoy the remaining years with high QOL 4 (5)
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economic incentive to target and even exploit cancer patients 
who have exhausted all other medical options. Nearly a 
third of CAM users in our study reported either traveling or 
intending to travel to a holistic center for CAM treatment, 
often times internationally. Considering that many CAM ser-
vices are not covered by insurance policies and force patients 
to pay out-of-pocket upwards of tens of thousands of dollars 
(Eisenberg et al. 1998), it is no surprise our study found that 
CAM users had a higher goal funds amounts than non-CAM 
users. Beyond the risk of economic exploitation, there is 
also the concern of safety: estimated 15 million adults are at 
risk for potential adverse interactions involving prescription 
medications and herbs or high-dose vitamin supplements 
(Eisenberg et al. 1998). The current lack of CAM regula-
tory oversight may contribute to a less safe, less-efficient, 
and less cost-effective system (Ventola 2010). Until there 
is adequate regulation in place to protect patients from dis-
honest advertising, physicians should educate themselves on 
common CAM therapies to provide comprehensive coun-
seling to patients who wish to use CAM.
The demographics of our patient population is consistent 
with prior literature that found CAM users more likely to 
be female and insured (Eisenberg et al. 1998; Subramani 
and Lakshmanaswamy 2017). In general, women are more 
likely to use CAM therapies than men (Barnes et al. 2002), 
with nearly 40% of women in the US reporting any recent 
CAM use (Upchurch et al. 2007). As breast cancer is the 
most frequently diagnosed cancer in women (Siegel et al. 
2019), it is no surprise that 31% of CAM users in our study 
report breast cancer. Prior studies have found that CAM 
usage increases after cancer diagnosis, with breast cancer 
survivors the most common among cancer survivors (Saquib 
et al. 2011). Women represent a potentially important group 
to study when understanding CAM usage and trends, since 
women are often the managers of health care in the house-
hold (Upchurch et al. 2007) and children are also more likely 
to use CAM if one parent already uses CAM (Barnes et al. 
2007). Our study also found that CAM users were more 
likely to have higher stages of cancer, which is consistent 
with a recent study of CAM usage (Johnson et al. 2018a). 
However, our study also discovered that CAM users are 
more likely to have a history of delayed, missed, or misdi-
agnosis, which is consistent with a prior study demonstrat-
ing an association between CAM use and delays in presen-
tation and diagnosis among breast cancer patients (Mujar 
et al. 2017). Whether this association is due to poor access 
to health care leading to increasing CAM usage, or CAM use 
that leads to delayed presentation and diagnosis, however, is 
uncertain, and more studies are needed.
Our study has several limitations. The study is observa-
tional and relies on personal narratives, which may not be 
entirely accurate and cannot be independently verified. Fraud 
has been shown to exist on gofundme.com (Victor 2019), but 
we cannot estimate rates of fraudulent data herein. Given 
that the narratives are also up to subjective interpretation, 
our analysis of the data may also be biased. Second, our 
study’s sample size is limited and selecting patients manu-
ally, albeit at random, may also be prone to sample bias and 
thus not generalizable to other populations. Finally, we were 
unable to extrapolate key patient demographic data regard-
ing race/ethnicity, education status, and income level from 
the campaign narratives. This information is important to 
establish a clearer picture of the typical CAM user, as well as 
identify any socio-economic factors associated with usage.
Conclusions
Our study found that CAM users are more higher cancer 
stage, have history of delayed, missed, or misdiagnosis, and 
request higher goal funds than non-CAM users.
Reasons for declining CCT include wanting to try CAM 
first, cancer already too aggressive or advanced, not want-
ing to go through side-effects of chemotherapy or radiation, 
and prioritizing quality of life in the remaining years. It is 
critical to understand the patient perspective of using CAM 
and/or declining CCT to provide holistic care and formulate 
a therapeutic patient-provider alliance, especially given the 
increased potential of exploitation and harm in this vulner-
able patient population. Physicians should further educate 
themselves on CAM to set realistic expectations and provide 
comprehensive counseling of the risks and benefits of CAM 
usage to cancer patients.
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